Advice on the designation of antimicrobials or groups of antimicrobials reserved for treatment of certain infections in humans - in relation to implementing measures under Article 37(5) of Regulation

June 21, 2022

Petri dish with bacteria growing.

Regulatory and Procedural Guideline

May 2022



“According to Article 37(5) of Regulation (EU) 2019/6 (‘the Regulation’), the European Commission shall adopt implementing acts designating antimicrobials or groups of antimicrobials to be reserved for the treatment of certain infections in humans. On 1 July 2019, the European Commission requested the European Medicines Agency to provide scientific recommendations on these ‘designated antimicrobials’. The EMA’s scientific recommendations, together with the methodology used and the outcome of evaluations of different antimicrobial groups, are provided in this advice. Supplementary information, including supporting monographs prepared for antiviral and antifungal classes/substances and the ATC (vet) codes for substances included in each antimicrobial grouping are presented in the Annex. The EMA has previously provided advice to the Commission in the context of the delegated act referenced under Article 37(4) of the Regulation, to establish the criteria to designate the antimicrobials to be reserved for humans [1]. Therefore, the CVMP considered that the expert group involved with this earlier advice should be requested also to assist in preparing the recommendations relating to the designated antimicrobials. This group consisted of experts from the European Network, EFSA, ECDC, EMA and external experts on human infectious diseases. The CVMP appointed additional experts from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and from national authorities, who assisted by reviewing working documents prepared for the evaluation by the core expert group. The CVMP is grateful to all the experts for their participation. The mandate and objectives of the expert group were agreed by the group itself and endorsed by the CVMP. The expert group submitted their report to the CVMP on 21 January 2022. The CVMP adopted the scientific advice on 16 February 2022.”

Download Regulatory and Procedural Guideline

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.


Small flags for the US and EU standing next to each other on a glass desk.

June 2, 2022

EMA appoints Chief Medical Officer

June 1, 2022 Steffen Thirstrup has been appointed as Chief Medical Officer of EMA. In this role, he will provide scientific leadership across EMA and its scientific committees to reinforce the...

Computer generated image of COVID-19

June 15, 2022

EMA adopts first list of critical medicines for COVID-19

News On 7 June 2022, EMA's Medicines Shortages Steering Group (MSSG) adopted the list of critical medicines for the COVID-19 public health emergency. The medicines included in the list are authorised...

Wayfinding signs with arrows showing 'right' and 'wrong.'

July 13, 2022

EMA Good clinical practice (GCP) inspection procedures

The Good Clinical Practice (GCP) Inspectors Working Group has developed procedures for the coordination, preparation, conduct and reporting of GCP inspections requested by the European Medicines...